02365nas a2200349   4500000000100000008004100001260003700042653002400079653005700103100001000160700001300170700001400183700001100197700001200208700001500220700001100235700001500246700001100261700001300272700001500285700001500300700001400315700001300329700001500342700001400357245005800371856009900429300001300528490000700541520145300548022001402001       2022                            d  bPublic Library of Science (PLoS)10aInfectious Diseases10aPublic Health, Environmental and Occupational Health1 aMow M1 aThean LJ1 aParnaby M1 aMani J1 aRafai E1 aSahukhan A1 aKama M1 aTuicakau M1 aKado J1 aRomani L1 aEngelman D1 aWhitfeld M1 aKaldor JM1 aSteer AC1 aCarvalho N1 aTurner HC00aCosts of mass drug administration for scabies in Fiji  uhttps://journals.plos.org/plosntds/article/file?id=10.1371/journal.pntd.0010147&type=printable  ae00101470 v163 a<p>In 2019, the Murdoch Children’s Research Institute in partnership with the Fiji Ministry of Health and Medical Services carried out an integrated mass drug administration (MDA) for the treatment of scabies and lymphatic filariasis in the Northern Division of Fiji (population estimate 131,914). We conducted a retrospective micro-costing exercise focused on the cost of scabies control in order to inform budgeting and policy decision making in an endemic setting. We collected detailed information on financial and economic costs incurred by both parties during the course of the MDA campaign (April 2018 to July 2019). We also conducted interviews with personnel involved in the financial administration of the MDA campaign. The economic cost of delivering two doses of ivermectin was US$4.88 per person. The cost of donated drugs accounted for 36.3% of total MDA costs. In this first large-scale MDA for the public health control of scabies, the estimated cost of delivering MDA per person for scabies was considerably more expensive than the costs reported for other neglected tropical diseases. The important cost drivers included the remuneration of health care workers who were extensively involved in the campaign, coverage of hard-to-reach, mainly rural populations and the two-dose regimen of ivermectin. These results highlight the importance of these cost determinants and can be used to plan current and future MDA programs.</p>
  a1935-2735